ISSN: 2375-4508
+44 1478 350008
Gary Levy
NIH/NICHD/PRAE,
10 Center Drive, Bldg 10, CRC, Rm 1-3140, Bethesda, MD 20892
Tanzania
Research Article
Does the Selective Progesterone Receptor Modulator Ulipristal Normalize the Uterine Cavity in Women with Leiomyoma?
Author(s): Gary Levy, Nilo Avila, Alicia Armstrong and Lynette NiemanGary Levy, Nilo Avila, Alicia Armstrong and Lynette Nieman
Objective: To determine if three months of chronic daily administration of ulipristal acetate (UPA), a selective progesterone receptor modulator, normalized the uterine cavity in women with leiomyoma.
Methods: Saline sonograms with abnormal uterine cavities from patients participating in a placebo controlled double blind randomized controlled trial evaluating UPA effect on leiomyoma volume were identified prior to initiation of therapy. They were reexamined after 12 weeks of UPA therapy. Normal uterine cavity was defined as having zero percent of leiomyoma volume inside the cavity on repeat sonohysterography. Patients with normal saline sonograms after 12 weeks of UPA therapy were compared with patients with sonographically persistently abnormal uterine cavities. Statistical analysis was performed using the Fisher’s exact test.
.. View More»
DOI:
10.4172/2165-7491.1000102